Carolinas Wealth Consulting’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Carolinas Wealth Consulting’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-214	Closed	-$19.1K	–	1166
2023 Q4	$19.1K	Hold	214	–	–	﹤0.01%	451
2023 Q3	$14.1K	Hold	214	–	–	﹤0.01%	475
2023 Q2	$17.8K	Hold	214	–	–	﹤0.01%	497
2023 Q1	$16.3K	Hold	214	–	–	﹤0.01%	529
2022 Q4	$17.7K	Sell	214 -1,500	-88%	-$121K	﹤0.01%	520
2022 Q3	$136K	Hold	1,714	–	–	0.03%	197
2022 Q2	$127K	Hold	1,714	–	–	0.03%	214
2022 Q1	$154K	Hold	1,714	–	–	0.03%	200
2021 Q4	$192K	Hold	1,714	–	–	0.04%	174
2021 Q3	$215K	Sell	1,714 -79	-4%	-$10.2K	0.05%	151
2021 Q2	$243K	Buy	1,793 +79	+5%	+$10.4K	0.05%	148
2021 Q1	$232K	Hold	1,714	–	–	0.06%	148
2020 Q4	$241K	Buy	1,714 +1,501	+705%	+$192K	0.06%	134
2020 Q3	$24K	Sell	213 -100	-32%	-$11.2K	0.01%	372
2020 Q2	$35K	Buy	+313	New	+$30.8K	0.01%	237

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Carolinas Wealth Consulting's XBI Position: Q1 2024 in Review

Carolinas Wealth Consulting sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 214 shares — an estimated $19.1K sold.

Carolinas Wealth Consulting first reported a position in XBI in Q2 2020 and held it in 15 quarters. The position peaked at $243K in Q2 2021. 782 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Carolinas Wealth Consulting reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Carolinas Wealth Consulting sold 214 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $19.1K.
Carolinas Wealth Consulting first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 15 quarters.
Carolinas Wealth Consulting's State Street SPDR S&P Biotech ETF position peaked at $243K in Q2 2021.
782 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2024, filed 15 May 2024.